These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12678459)

  • 21. Real-world patient-reported rates of non-severe hypoglycaemic events in Germany.
    Kulzer B; Seitz L; Kern W
    Exp Clin Endocrinol Diabetes; 2014 Mar; 122(3):167-72. PubMed ID: 24643694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Vanderheiden A; Harrison L; Warshauer J; Li X; Adams-Huet B; Lingvay I
    JAMA Intern Med; 2016 Jul; 176(7):939-47. PubMed ID: 27273731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoglycaemia during intensified insulin therapy of children and adolescents.
    Ludvigsson J; Nordfeldt S
    J Pediatr Endocrinol Metab; 1998 Mar; 11 Suppl 1():159-66. PubMed ID: 9642655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exorcising the specter of nighttime hypoglycemia.
    Scheiner G
    Diabetes Self Manag; 2012; 29(1):16, 18-20. PubMed ID: 22482132
    [No Abstract]   [Full Text] [Related]  

  • 25. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis.
    Benkhadra K; Alahdab F; Tamhane SU; McCoy RG; Prokop LJ; Murad MH
    Endocrine; 2017 Jan; 55(1):77-84. PubMed ID: 27477293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
    Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
    Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Basal insulin therapy in patients with type 2 diabetes].
    Vuignier Y; Roukain A; Kosinski C; Wojtusciszyn A
    Rev Med Suisse; 2021 Jun; 17(741):1078-1082. PubMed ID: 34077039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin therapy for type 2 diabetes.
    Swinnen SG; Hoekstra JB; DeVries JH
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S253-9. PubMed ID: 19875560
    [No Abstract]   [Full Text] [Related]  

  • 29. Fasting during the holy month of Ramadan among older children and adolescents with type 1 diabetes in Kuwait.
    Mohamed K; Al-Abdulrazzaq D; Fayed A; El Busairi E; Al Shawaf F; Abdul-Rasoul M; Shaltout AA
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):843-849. PubMed ID: 31318694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Summaries for patients. Inhaled insulin with or instead of oral medications for type 2 diabetes.
    Ann Intern Med; 2005 Oct; 143(8):I28. PubMed ID: 16230717
    [No Abstract]   [Full Text] [Related]  

  • 31. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.
    Noh RM; Graveling AJ; Frier BM
    Expert Opin Pharmacother; 2011 Oct; 12(14):2161-75. PubMed ID: 21668402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Oral antidiabetic agents and hypoglycemia in elderly patients].
    Porzi J; Petriccioli N; Malacarne S
    Rev Med Suisse; 2020 Feb; 16(680):264-267. PubMed ID: 32022491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Factors limiting glycaemic control in insulin-treated type 2 diabetes].
    Ferencz V; Domján B; Gerő L; Tänczer T; Tabák GÁ
    Orv Hetil; 2015 Sep; 156(36):1443-50. PubMed ID: 26320598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy in early insulin initiation as comprehensive therapy for patients with type 2 diabetes in primary health care centers.
    Pranoto A; Novida H; Prajitno JH; Tjokroprawiro A
    Acta Med Indones; 2015 Apr; 47(2):104-10. PubMed ID: 26260552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
    Massi Benedetti M; Humburg E; Dressler A; Ziemen M
    Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
    Hollander PA; Levy P; Fineman MS; Maggs DG; Shen LZ; Strobel SA; Weyer C; Kolterman OG
    Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions.
    Perreault L; Vincent L; Neumiller JJ; Santos-Cavaiola T
    J Am Board Fam Med; 2019; 32(3):431-447. PubMed ID: 31068410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of structured group education on glycemic control and hypoglycemia in insulin-treated patients.
    Koev DJ; Tankova TI; Kozlovski PG
    Diabetes Care; 2003 Jan; 26(1):251. PubMed ID: 12502698
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
    Karl DM; Gill J; Zhou R; Riddle MC
    Diabetes Obes Metab; 2013 Jul; 15(7):622-8. PubMed ID: 23350795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.